Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL
Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of first-line gemcitabine, oxaliplatin, and asparaginase
(GELOX) with concurrent involved-field radiation therapy for patients in newly diagnosed
stage IE/IIE ENKTL.